Please Wait
Applying Filters...
menu
    • menu
    IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Zoliflodacin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 23,569Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Innoviva Specialty Therapeutics Presents Zoliflodacin Phase 3
    Innoviva Specialty Therapeutics Presents Zoliflodacin Phase 3

    20 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-20/innoviva-specialty-therapeutics-announces-oral-presentation-featuring-new-analyses-from-the-zoliflod

    PHARMIWEB
    20 Oct 2025
    Share Share
    Innoviva To Deliver Six ID & Critical Care Talks At IDWeek 2025
    Innoviva To Deliver Six ID & Critical Care Talks At IDWeek 2025

    07 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-07/innoviva-specialty-therapeutics-to-deliver-six-presentations-from-its-infectious-diseases-and-critic

    PHARMIWEB
    07 Oct 2025
    Share Share
    FDA Grants Priority Review for Zoliflodacin NDA for Gonorrhea
    FDA Grants Priority Review for Zoliflodacin NDA for Gonorrhea

    12 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250612432209/en/FDA-Grants-Priority-Review-for-Zoliflodacin-New-Drug-Application-for-the-Treatment-of-Uncomplicated-Gonorrhea-and-Assigns-Target-PDUFA-Date-of-December-15-2025

    BUSINESSWIRE
    12 Jun 2025
    Share Share
    Innoviva Specialty Therapeutics: FDA Accepts Zoliflodacin NDA
    Innoviva Specialty Therapeutics: FDA Accepts Zoliflodacin NDA

    10 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250610102070/en/Innoviva-Specialty-Therapeutics-Receives-FDA-New-Drug-Application-Acceptance-for-Zoliflodacin-a-First-in-Class-Oral-Antibiotic-for-Uncomplicated-Gonorrhea-in-Adults

    BUSINESSWIRE
    10 Jun 2025
    Share Share
    Innoviva's Zoliflodacin Gonorrhea Phase 3 Data at ESCMID
    Innoviva's Zoliflodacin Gonorrhea Phase 3 Data at ESCMID

    24 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240424323555/en

    BUSINESSWIRE
    24 Apr 2024
    Share Share
    Entasis Therapeutics and the Global Antibiotic Research & Development Partnership
    Entasis Therapeutics and the Global Antibiotic Research & Development Partnership

    22 Nov 2018

    // PRESS RELEASE

    https://www.dndi.org/2017/media-centre/press-releases/entasis-therapeutics-and-gardp-to-develop-new-treatment-for-drug-resistant-gonorrhea/

    PRESS RELEASE
    22 Nov 2018
    Share Share